Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1991 participants.

Also called NCT02730377

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,991 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02730377
  • EudraCT 2015-002417-29
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Colombia, India, Latvia, Lebanon, Puerto Rico, Russia, Serbia, Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02730377. Randomized; no masking; primary purpose treatment. Start 2016-03-28 (actual); primary completion 2019-08-05 (actual). Results posted on 2020-07-07.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Acronym
LIRA-PRIME
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
liraglutide
Intervention (Drug)
alpha-glucosidase inhibitors
Intervention (Drug)
DPP-4 inhibitors
Intervention (Drug)
meglitinides
Intervention (Drug)
SGLT-2 inhibitors
Intervention (Drug)
sulphonylurea
Intervention (Drug)
thiazolidinediones
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct02730377
Content hash
65ac89cedeb877fe341d31a532e9700eebe98e3764c9d7494cf574cff4f10bab